Why did Abbott Laboratories (ABT) stock move recently?

On 7/27/2026, Abbott Laboratories moved +3.7% — ABT rose on continued momentum from its July 16 Q2 earnings beat and raised full-year 2026 adjusted EPS guidance (to $5.45-$5.60), plus today's FDA approval of Freenome’s SimpleScreen CRC blood test that Abbott will exclusively commercialize in the U.S. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Abbott Laboratories (ABT) overvalued or fairly valued?

MarketChacha shows Abbott Laboratories's valuation in context — a trailing P/E of about 32.6, a forward P/E of about 17.9, a price-to-book of about 3.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Abbott Laboratories's reported profit turn into cash?

Over 3 years, about 99% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement. MarketChacha computes this cash-conversion check (0.99×) from reported figures — education, not a rating.

What is Abbott Laboratories's revenue?

Abbott Laboratories reported revenue of $44.3B for FY2025, with net profit of $6.5B, per official filings.

What is the share price of Abbott Laboratories (ABT)?

Abbott Laboratories last traded at $108.33 (-1.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Abbott Laboratories

ABT · NYSE · Healthcare · United States

Snapshot

TickerABT

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees122,000

HeadquartersAbbott Park, United States

Websitewww.abbott.com

Filings tracked18

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Who owns it

Insiders0.5%
Institutions81.9%
Public & other17.6%

3,809 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.82%
Vanguard Capital Management LLC6.57%
State Street Corporation4.68%
Charles Schwab Investment Management, Inc.3.45%
Vanguard Portfolio Management LLC2.83%
Geode Capital Management, LLC2.27%
Capital Research Global Investors2.13%
Capital International Investors2.00%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years, about 99% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Cash conversion0.99×

Over 3 years, about 99% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Net margin trend14.3% → 14.7%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 5% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $13.5B · EPS 1.64

Est. earnings growth +9.2%

Next fiscal year

Rev $54.6B · EPS 6.06

Est. earnings growth +9.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$44.3B

Net margin

14.7%

ROE

12.5%

Revenue CAGR (2y)

+5.1%

Profit CAGR (2y)

+6.8%

EPS (FY2025)

3.72

Net profit (FY2025)

$6.5B

Ask MarketChacha about ABT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
ABT rose on continued momentum from its July 16 Q2 earnings beat and raised full-year 2026 adjusted EPS guidance (to $5.45-$5.60), plus today's FDA approval of Freenome’s SimpleScreen CRC blood test that Abbott will exclusively commercialize in the U.S.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$44.3B	$6.5B	3.72	14.7%	12.5%
FY2024	$42.0B	$13.4B	7.64	31.9%	28.1%
FY2023	$40.1B	$5.7B	3.26	14.3%	14.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$11.2B	$1.1B	0.61	9.6%
2025Q3	$11.4B	$1.6B	0.94	14.5%
2025Q2	$11.1B	$1.8B	1.01	16.0%
2025Q1	$10.4B	$1.3B	0.76	12.8%
2024Q3	$10.6B	$1.6B	0.94	15.5%
2024Q2	$10.4B	$1.3B	0.74	12.5%
2024Q1	$10.0B	$1.2B	0.70	12.3%
2023Q3	$10.1B	$1.4B	0.82	14.2%
2023Q2	$10.0B	$1.4B	0.78	13.8%
2023Q1	$9.7B	$1.3B	0.75	13.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/28/2026
8-K — Results of operations, Exhibits
SEC7/16/2026material
10-Q filing
SEC4/29/2026
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC4/27/2026material
8-K — Other events, Exhibits
SEC4/17/2026material
8-K — Results of operations, Exhibits
SEC4/16/2026material
8-K — Other events, Exhibits
SEC3/23/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC3/9/2026material
8-K — Material agreement, Exhibits
SEC2/26/2026material
10-K filing
SEC2/20/2026
8-K — Bylaw/charter change, Exhibits
SEC2/20/2026material
8-K — Results of operations, Exhibits
SEC1/22/2026material

2025

8-K — Executive/director change, Bylaw/charter change, Exhibits
SEC12/12/2025material
8-K — Exhibits
SEC11/21/2025material
8-K — Material agreement, Reg FD disclosure, Other events, Exhibits
SEC11/20/2025material
10-Q filing
SEC10/29/2025
8-K — Results of operations, Exhibits
SEC10/15/2025material
10-Q filing
SEC7/30/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.